As anyone affected by a rare disease knows, treating the illness while trying to go about everyday life is an expensive undertaking. But exactly how expensive — in terms of direct and indirect costs across rare disease populations — might still come as a surprise: almost…
News
Imara is opening higher dose arms in two Phase 2b trials assessing the safety and efficacy of IMR-687, its potential therapy for sickle cell disease (SCD) and beta-thalassemia, in patients with these inherited blood disorders, the company announced. The decision, which applies to the Ardent (NCT04474314) and…
Graphite Bio has raised $150 million in Series B funding to expand and advance the clinical development of its pipeline of investigational gene-editing therapies — including GPH101, a potentially curative treatment for sickle cell disease (SCD). In addition…
Adding Cell Source’s special class of immune cell, Veto T-cells, to blood stem cells from an unrelated donor led to a successful transplant and to the production of normal red blood cells in a mouse model of sickle cell disease (SCD), the company announced. The preclinical Cell Source-sponsored…
Global Blood Therapeutics (GBT) has opened its grant program — the Access to Excellent Care for Sickle Cell Patients (ACCEL), now in its third year — to proposals supporting programs aiming to improve access to high-quality healthcare for people with sickle cell disease (SCD). GBT will donate up…
Registration is open for the 8th annual “Walk with the Stars,” one of the largest fundraisers organized by the Sickle Cell Disease Association of America (SCDAA) that supports the development of better treatments and a cure for sickle cell disease (SCD). All proceeds from the July 10 event…
LentiGlobin, Bluebird Bio’s investigational gene therapy for sickle cell disease (SCD), is unlikely to be the cause of a blood cancer that arose in one of the patients who received the therapy in an early clinical trial, according to new analyses. In February, Bluebird paused two clinical…
Many diseases have their own awareness color — breast cancer is pink, muscular dystrophy is green, and AIDS is red, for example — but what’s the significance of pink, green, blue, and purple lights side-by-side? These are the colors most often used to represent Rare Disease Day. This…
The opioid crisis, along with the stigma of suspected drug use, and racial bias all contribute to make treatment access more difficult for people with sickle cell disease (SCD). That was the take-home message of the…
Vascular electrical stimulation therapy (VEST), a form of local electrical stimulation applied to the skin, can lower the duration of painful vaso-occlusive crises (VOCs) in patients with sickle cell disease (SCD), according to data from a Phase 2 clinical trial. Based on these findings, study investigators argue that…
Recent Posts
- Disease burden heavy for SCD patients in US, despite promise of gene therapy
- The conversation we avoid: Telling children they have sickle cell disease
- New study finds distinct molecular signatures in newborns with SCT
- Blood test may improve kidney damage detection in children with SCD
- Understanding the impact of leg ulcers in sickle cell disease
- Asthma seven times more likely in SCD children than in unaffected siblings
- Sickle cell drug at high dose eases anemia symptoms in severe SCD
- Researchers urge more talk on menstrual pain in sickle cell clinics
- Sickle cell patients shifting to adult care visit ER more often: US study
- Early results of trial testing tebapivat in SCD expected later this year